New York City health officials analyzed 9,765 virus specimens collected citywide between Jan. 1 and April 5.
The hospitalization rate for people infected with the B.1.526 variant was 4.3 percent, compared to 5.8 percent for those with the B.1.1.7 variant first identified in the U.K.
Overall, reinfections were rare. Researchers found no difference in possible reinfection rates among those infected with the U.K. or New York City variant.
Researchers cautioned the data is preliminary and only covers about 3 percent of all COVID-19 cases in the city during the study period, according to The New York Times.
“Because relatively few specimens were sequenced over the study period, the statistical power might have been insufficient to detect modest differences in rates of uncommon outcomes such as breakthrough infection or re-infection,” they wrote.
To view the full study, click here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
